June 17, 2025
PRESS RELEASE 12 June 2025 On 7 May 2025, the FDA approved an IND application enabling Myrio’s lead product (PHOX2B PC-CAR T) to enter human trials. […]
June 6, 2025
6th June, 2025 Key Highlights Myrio Tx and University of Pennsylvania’s long standing collaboration has yielded compelling results in developing first-in-class and best-in-class next-generation cancer therapies […]
April 15, 2025
March 14, 2025
The Myrio team recently participated in the Spring edition of the Society for Immunotherapy of Cancer (SITC), where Matt Beasley (Co-founder, CSO) and Dr. Lauren Pitt (Head of Preclinical) presented at […]
November 12, 2024
Psaio Therapeutics (subsidery of Myrio Therapeutics) is thrilled to announce that it has been selected as a finalist in the 2024 ANZ Advance Biotech Grant Program […]
April 8, 2024
31 May 2023, MELBOURNE, Australia – Australia’s sovereign pandemic preparedness has received a boost with Myrio Therapeutics Pty Ltd (Myrio), a privately-owned Australian biotechnology firm with a […]
April 8, 2024
Myrio Therapeutics Pty Ltd (Myrio) today announced ground-breaking findings published in the Journal Nature. The study, titled Therapeutic Targeting of Intracellular Oncoproteins with Peptide-Centric CAR T Cells, used […]
April 8, 2024
Myrio is proud to be part of the global CoVIC consortium, providing antibodies in the fight against COVID-19. The results of the consortiums work have this […]
April 8, 2024
CAR TCR Summit: Myrio Tx shares transformational approach to targeted human antibody-based therapies
Myrio Therapeutics (Myrio Tx) is driving a new frontier of antibody-based therapies as the company’s Retained DisplayTM (ReD) antibody platform offers identification of highly specific human antibodies that […]